- Almac Clinical Services has completed a multi-million-pound cold chain expansion at its Craigavon, Northern Ireland site.
- The investment includes a new Ultra-Low Temperature facility and significant increases in packaging and storage capacity.
Almac Clinical Services, part of the Almac Group, has announced the completion of a multi-million-pound expansion of its cold chain capabilities at its global headquarters in Craigavon, Northern Ireland. The move is part of the company’s broader global strategy to meet growing demand for advanced clinical trial supply services.
The Craigavon site now features a purpose-built Ultra-Low Temperature facility, which has tripled the company’s -15°C to -25°C secondary packaging capacity and doubled storage capacity at -60°C to -80°C. These enhancements support the increasing needs of biopharmaceutical clients, particularly those developing Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies.
Additional upgrades at the site include a redesigned cold chain management centre with expanded 2°C to 8°C secondary production rooms, new label printing and checking suites, and enhanced packaging design capabilities. Almac stated that these changes have increased cold chain packaging capacity by over 60%.
The investment aligns with parallel infrastructure improvements at Almac’s North Carolina and Singapore facilities, reinforcing the company’s global cold chain network.
“As the number of biological products in clinical development continues to grow, it is important that Almac can offer both the capability and capacity that clients will require in the future,” said Dr Robert Dunlop, President and Managing Director of Almac Clinical Services. “These investments are a testament to our strategic vision to stay ahead of industry needs.”
